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Abstract. Background/Aim: Gremlin1 (GREM1) plays an
important role in certain malignancies by antagonising bone
morphogenetic proteins and regulating angiogenesis
directly/indirectly. The present study aimed to investigate the
role of Gremlin1 in the development and progression of
gastric cancer (GC). Materials and Methods: Expression of
GREM1 in GCs was examined using quantitative real time
PCR and The Cancer Genomic Atlas (TCGA) data. Influence
on cellular functions was determined in both Gremlin1
knockdown and overexpression cell line models. Results:
GREM1 expression was up-regulated in GCs, which was
correlated with poorer survival. Increased GREM1
expression was significantly correlated with tumour
growth/invasion and lymphatic metastasis. Gremlin1
promoted proliferation and tumourigenic capacity of GC
cells in vitro. GREM1 expression was associated with
epithelial mesenchymal transition (EMT), angiogenesis and
lymphangiogenesis in GC. Conclusion: Increased GREM1
expression in GCs is associated with disease progression and
poor prognosis in which EMT, angiogenesis and
lymphangiogenesis are likely involved. 
Gastric cancer (GC) is one of the leading cancers in China
accounting for 42.6% of the new cases diagnosed and 45.0%
of the deaths due to the disease worldwide each year (1).
Bone morphogenetic proteins (BMPs) play an important part
in regulating the homeostasis of the gastric epithelium and
tumorigenesis (2, 3). BMP signaling regulates the
homeostasis of the gastric epithelium through its ability to
control the biological functions of the parietal cells (2).
Inhibition of BMP signaling in the gastric mucosa leads to
severe abnormalities in the proliferation, maturation, and
differentiation of several lineages of gastric epithelial cells,
and further, form metaplasia, atypical hyperplasia and
tumours (2, 4). For example, BMP2 inhibits proliferation of
GC cells. Methylation-related down-regulation of BMP2 has
been observed in GCs (5, 6). Other studies have also
detected a decrease in the expression of molecules in the
BMP signaling pathway in gastric cancer (7), which reflects
the inhibitory effect of BMPs on gastric cancer proliferation.
BMPs are also related to metastasis of GC. BMP4 expression
has been shown to be inversely correlated with the
prevalence of metastasis to lymph nodes and also with local
invasion (8). However, controversy remains for the exact
role played by BMPs in GC. For instance, BMP2 plays a
positive role in pathological differentiation and lymph node
metastasis through activation of the PI3K/AKT and MAPK
pathways (9). It is suggested that GC cells may benefit from
either the loss of BMPs for their proliferation or from the
BMP-induced invasive traits. Further investigation on the
role played by BMPs in GC warrants a better and more
comprehensive understanding of the disease. 
Gremlin1 acts as an antagonist by preventing binding of bone
morphogenetic proteins to their receptors. It is one of the most
important direct antagonists of BMP2,4,7, which can block the
BMP signalling pathway. It has been reported that Gremlin1
plays an important part in regulating organogenesis, body
patterning and tissue differentiation (10, 11). Emerging evidence
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has shown that Gremlin1 is expressed in a number of
malignancies including skin cancer, GC, lung cancer, kidney
cancer, testicular cancer and so on (12). Immunochemical
staining showed that Gremlin1 is positively expressed in GC
tumours (12-14). Yamasaki et al. have shown that the expression
of Gremlin1 was correlated with shallower tumour depth,
smaller tumour size, less nodal involvement, vessel invasion and
also a better 5-year survival rate (13). However, the molecular
and cellular machinery underlying the involvement of Gremlin1
in the disease progression of GC remains unknown. In this
study, in addition to the quantitative analysis of Gremlin1 in two
different cohorts of GC tumours, GC cell lines were employed
to investigate the influence of knockdown or overexpression of
Gemlin1 on cellular functions. 
Materials and Methods
GC tumour samples. GC tumours (n=321) and paired adjacent
control healthy tissues (n=183) were collected immediately after
surgery at the Peking University Cancer Hospital (PUCH) with
written consent from all the patients. The specimens were stored
at –80˚C until use. The collection and usage of the GC specimens
were carried out in accordance with protocols and procedures
approved by the Peking University Cancer Hospital Research Ethics
Committee.
Analysis of GREM1 expression in human GC tissues using gene
expression array data. We evaluated the expression of GREM1 in
gastric cancer tissues (n=274) compared to normal gastric tissues
(n=33) in the gastric adenocarcinoma cohort of The Cancer Gene
Atlas (TCGA) database. The correlations between the GREM1
expression and the clinicopathological parameters and survival
were analysed.
Kaplan–Meier survival analysis was also performed to evaluate
the relationship of GREM1 with the prognosis of patients with an
auto-selected cut-off value. 
TCGA database was also employed for the evaluation of the
correlation between GREM1 and key genes relevant to the
hallmarks of cancer including epithelial mesenchymal transition
(EMT), angiogenesis and lymphangiogenesis.
RNA isolation and reverse transcription-polymerase chain reaction
(RT-PCR). Total RNA was extracted using TRI Reagent kit (Sigma-
Aldrich, Inc., Dorset, UK). Reverse transcription was performed to
convert 2 μg of total RNA to complementary DNA using the
GoScript™ Reverse Transcription System (Promega, Southampton,
UK). Polymerase chain reactions were subsequently carried out for
amplification of GREM1 (forward:5’-CTGCTGAAGGGAAAA
AGAA; reverse:5’-GATGGATATGCAACGACACT), SNAI1
(forward:5’-CGCTCTTTCCTCGTCAG; reverse:5’-GTTGCAG
TATTTGCAGTTGA), SNAI2 (forward:5’-CTCTCCTCTTTCCGG
ATACT; reverse:5’-AGCAGTTTTTGCACTGGTAT), TWIST1
(forward:5’-AGCAACAGCGAGGAAGAG; reverse: 5’-GAGGA
CCTGGTAGAGGAAGT), ID1 (forward:5’-TCAACGGCGA
GATCAG; reverse:5’-GATCGTCCGCAGGAA), ID2 (forward:5’-
GAACACGGATATCAGCATC; reverse:5’-ACAGTGCTTTGCT
GTCATTT), ID3 (forward:5’-GCGTCATCGACTACATTCTC;
reverse:5’-GTCGTTGGAGATGACAAGTT), VEGFA (forward:5’-
GAGCCGGAGAGGGAG; reverse:5’-CTGGGACCACTTGGCAT),
VEGFC (forward:5’-AGTCGCGACAAACACCTTCT; reverse:5’-
CATCCAGCTCCTTGTTTGGT), VEGFD (forward:5’-TGGA
ACGATCTGAACAGCAG; reverse:5’-TTCTTCAGGGATCTGGA
TGG) and KDR (forward:5’-AACTGAAGACAGGCTACTTG;
reverse:5’-GTCGTTCACAATGTTCATCC). After an initial 5-min
denaturation step, the target gene was amplified for 25-30 cycles
(95˚C for 30 sec, 55˚C for 30 sec and 72˚C for 30 sec), followed by
a final extension at 72˚C for 5 min. GAPDH (forward: 5’-
GGCTGCTTTTAACTCTGGTA; reverse: 5’-GACTGTGGTCA
TGAGTCCTT) was employed as a house-keeping gene.
Cell lines and cell culture. HGC27 and AGS cell lines were
purchased from Sigma. 293T cells were obtained from the American
Type Culture Collection (ATCC, Rockville, MD, USA). MKN7,
NUGC4, MKN45 cell lines were kindly provided by Peking
University Cancer Hospital (PUCH). All cell lines were routinely
cultured at 37˚C with 5% CO2 and 95% humidity in Dulbecco’s
modified Eagle medium (DMEM; Sigma-Aldrich) supplemented
with 5% foetal bovine serum (FBS; HyClone, Fisher Scientific UK
Ltd., Loughborough, UK).
Western blot. Cells were lysed when they reached 70%-90%
confluence. Protein concentration was measured with a DC protein
assay kit (Bio-Rad Laboratories, Watford, UK). Cell lysates of 30
μg total protein for each sample were separated on 10% SDS-PAGE
and then electroblotted onto PVDF membranes. The blotted
membranes were incubated for overnight at 4˚C with primary
antibodies GAPDH (1:2000, sc-47724, Santa Cruz, Princeton, New
Jersey, United States) and Gremlin1 (1:500, sc-515877, Santa Cruz),
and then with the corresponding anti-mouse secondary antibody
(A5278, 1:1000, Sigma-Aldrich) for 1 hour. Protein bands were
visualised with a chemiluminescence detection kit (EZ-ECL,
Biological Industries, Cromwell, CT, USA) and documented
photographed using Syngene imager (Syngene International Ltd.,
Cambridge, UK). 
Gremlin1 knockdown and overexpression. We obtained the lentiviral
GREM1 shRNA (CTGAAGCGAGACTGGTGCAAA) and scramble
control (CCTAAGGTTAAGTCGCCCTCG) from Cyagen
Biosciences (Santa Clara, CA, USA). Both GREM1 shRNA and
scramble shRNA plasmid vectors carried two selective markers in
mammalian cells, EGFP and neomycin. Lentiviral particles were
packaged using 293T cells together with pMD2G and pSPAX2
plasmid vectors. The full-length human Gremlin1 coding sequence
was amplified from a cDNA library derived from normal prostate
tissue which was subsequently cloned into pEF6/V5-His TOPO TA
plasmid vector (Invitrogen Ltd., Inchinnan, Renfrewshire, UK). The
recombinant Gremlin1 plasmid vector and empty vector were
separately transfected into the AGS cells using electroporation. The
empty vectors were employed as controls. G418 (500 μg/ml) and
blasticidin (5 μg/ml) were used for the selection. PCR and western
blot were used to verify the expression of Gremlin1 in the
transfected cells following transduction and transfection.
In vitro cell growth assay. The cells were seeded into 96-well plates
at 3000 cells/well in 200 μl medium and cultured for up to 5 days.
The cells were then fixed using 4% formaldehyde and stained with
0.1% crystal violet. Excessive crystal violet was rinsed with tap
water. The stained crystal violet was dissolved with 10% acetic
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acid for determination of the absorbance at a wavelength of 540
nm with a spectrophotometer (Bio-Tek Instruments Inc, Winooski,
VT, USA).
In vitro clonogenic assay. Three hundred cells were seeded into each
well of a 6-well plate. After a 10-days in culture, the cells were
fixed with 4% formaldehyde followed by staining with 0.1% crystal
violet. The number of colonies were then counted under an inverted
microscope.
In vitro cell adhesion assay. A 96-well plate was pre-coated with
Matrigel (5 μg/well) (BD Biosciences, Oxford, UK). Cells were
seeded into each well at a density of 30,000 cells/200 μl medium.
Non-adherent cells were washed off gently with PBS buffer after
incubation for 40 min. Adhered cells were then fixed and stained
with crystal violet. The absorbance was measured at 540 nm after
the stained crystal violet was dissolved with 10% acetic acid.
In vitro cell invasion assay. Transwell inserts (8 μm pore, Greiner
Bio-One Ltd., Stonehouse, UK) were coated with a thin layer of
Matrigel (50 μg/insert) and air dried. After rehydration with
medium, 30,000 cells were seeded per insert followed by incubation
for 3 days. The Matrigel coating and non-invaded cells were
removed using a cotton swap. Invaded cells were fixed and stained
0.1% crystal violet which was resolved in 10% acetic acid. The
absorbance was measured using the spectrophotometer.
In vitro scratch wounding assays. The cells were seeded into a 6-
well plate (two million cells per well). After an overnight culture,
the cells were then scratched using a 200 μl pipette tip to create a
wound. The wound closure was monitored for 5 h using inverted
microscopy equipped with a digital camera. The migration was
measured using ImageJ.
Statistical analysis. Following a normality check, t-test was
employed for normally distributed data whilst non-normally
distributed data were analysed using Mann-Whitney test or One-
way ANOVA test. Differences were regarded as statistically
significant when the p-value was less than 0.05. Kaplan–Meier
survival analyses were performed using both an online platform
(kmplot.com) (15) and SPSS statistical software (v25, IBM SPSS,
Portsmouth, UK).
Results
Elevated expression of GREM1 in GCs is associated with
poor prognosis. Expression of GREM1 in gastric cancer
tissues was quantitatively analysed in comparison with
adjacent normal gastric tissues in two GC cohorts from the
TCGA and PUCH. As shown in Figure 1A, in the TCGA
cohort, the expression of GREM1 in gastric cancer tissues
(n=274) was significantly higher than its expression in
normal gastric tissues (n=33). Quantitative real time PCR
also revealed a higher expression of GREM1 in gastric
cancer tissues (n=317) in comparison with adjacent normal
gastric tissues (n=181) in the PUCH cohort (Table I).
Further analyses showed a correlation between GREM1
expression and clinical pathological characteristics of the
disease in the TCGA cohort. GREM1 expression was
significantly increased in tumours with a more invasive
phenotype according to the T stages of the tumours (Figure
1B). The increased expression of GREM1 was also observed
in the tumours with lymphatic metastases (Figure 1C). The
expression of GREM1 was also associated with the overall
TNM staging of the disease, though no marked difference
was seen in the tumours that developed distant metastases
(Figure 1D and E). However, there was no correlation
between the expression of GREM1 and the TNM staging in
the PUCH cohort (Table I).
Kaplan–Meier survival analyses showed that overall
survival (OS) of patients with high expression of GREM1
(median=15.03 months) was significantly shorter than that
in those with lower GREM1 expressing tumours
(median=25.87 months) (Figure 1F). Similarly, the elevated
expression of GREM1 was also significantly associated with
a shorter progression-free survival (PFS, median=9.4
months), compared with those that had lower expression
levels of GREM1 (median=13.03 months, p<0.001) (Figure
1G). In addition, Kaplan–Meier survival analysis of GREM1
in the TCGA cohort also showed that patients with higher
expression of GREM1 had poorer overall survival (data not
shown). 
Gremlin1 promotes proliferation of GC cells and
tumourigenesis in vitro. In order to explore the biological
functions of Gremlin1 in GC cells, we determined the
expression of GREM1 in GC cell lines, i.e. HGC27, MKN7,
NUGC4, MKN45 and AGS using PCR (Figure 2A). GREM1
is expressed at a relatively lower level in AGS cells in
comparison with the other four GC cell lines. Knockdown and
overexpression of Gremlin1 were subsequently established in
HGC27GREM1sh and AGSGREM1exp using the lentiviral
GREM1 shRNA and Gremlin1 overexpression plasmid
vectors, respectively (Figure 2B), in comparison with the
corresponding controls, i.e. HGC27SC with scrambled shRNA
and AGSpEF with the empty plasmid vector.
Growth assays showed that Gremlin1 knockdown resulted
in reduced proliferation of HGC27GREM1sh cells (Figure 2C),
while increased proliferation was observed in AGSGREM1exp
cells following the overexpression of Gremlin1 (Figure 2D).
Similar impact was seen on the colony formation (Figure 2E
and F). The number of colonies was reduced in the
HGC27GREM1sh cells, while it was increased in AGSGREM1exp
cells compared with the corresponding controls. 
The effect of Gremlin1 on cell proliferation was further
validated in an in vitro 3D spheroid model (Figure 2G and
I). The growth of spheroids formed by the HGC27GREM1sh
cells was marginally reduced compared with the HGC27SC
control cells (Figure 2G and H). A marked increase was seen
in the size of the AGSGREM1exp cell formed spheroids
compared with the controls (Figure 2I and J).
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Gremlin1 regulates adhesion, invasion and migration of GC
cells. Gemlin1 knockdown resulted in a significant decrease
in the adhesion of HGC27GREM1sh cells, while increased
adherence was observed following Gremlin1 overexpression
in AGS cells (Figure 3A).
As shown in Figure 3B, the AGSGREM1exp cells exhibited
enhanced invasiveness, while a marginal decrease was seen
in the HGC27 cells following the knockdown of Gremlin1. 
Wound assays showed that HGC27GREM1sh cells migrated
faster than the control cells (Figure 3C and D), while an obvious
reduction was evident in the migration of AGSGREM1exp cells
compared with AGSpEF cells (Figure 3E and F).
GREM1 and epithelial mesenchymal transition (EMT) in GC.
BMP-induced EMT plays an important role in disease
progression of solid tumours. Expression of EMT-related genes,
particularly of BMP responsive genes were determined in both
HGC27GREM1sh and AGSGREM1exp cells compared with their
corresponding control cells. An elevated expression of ID3 was
seen in the HGC27GREM1sh cells, while a subtle reduction was
seen in its expression by the AGSGREM1exp cells (Figure 4A).
Similarly, a subtle decrease was seen in the expression of ID2
by the AGSGREM1exp cells. An increased expression was seen
for both Snail Family Transcriptional Repressor 2 (SNAI2) and
Snail Family Transcriptional Repressor 1 (SNAI1) in the
AGSGREM1exp cells. 
Furthermore, we analysed the correlation between GREM1
and these EMT-related genes in the TCGA GC cohort. It was
found that the expression levels of GREM1 were negatively
correlated with the expression of ID1 and ID2, but positively
correlated with SNAI1, SNAI2 and the Twist family BHLH
transcription factor 1 (TWIST1) (Figure 4).
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Table I. The expression of Grem1 transcripts in gastric cancer.
Category                                                                              No.                                               Median (IQR)                                               p-Value
Tumour                                Tumour                                   317                                     203849 (28473-1005293)                                       0.000
                                            Normal                                    181                                       55085 (12783-166711)                                              
Gender                                 Male                                        225                                     209424 (31409-1041133)                                      0.5602
                                            Female                                     92                                       177906 (26123-954673)                                             
Location                              Cardia                                      66                                      293481 (58736-1141462)                           0.5524 (vs. Polorus)
                                            Fundus                                     21                                      651974 (38903-3150797)                              0.4 (vs. Polorus)
                                            Corpus                                     60                                       117226 (28635-850115)                            0.4049 (vs. Polorus)
                                            Pylorus                                    130                                     244602 (35278-1086536)                                            
Differentiation                    Diff-H                                       1                                                 1.10E-3 (*-*)                                                      
                                            Diff-HM                                    6                                          72539 (6613-305557)                               0.2678 (vs. Diff-L)
                                            Diff-M                                     61                                      168387 (23130-1016104)                            0.6933 (vs. Diff-L)
                                            Diff-ML                                   81                                      339781 (43955-1125686)                            0.0792 (vs. Diff-L)
                                            Diff-L                                      135                                      147390 (25854-592435)                                             
T stage                                 T1                                             16                                        77670 (14684-348948)                                 0.3198 (vs. T4)
                                            T2                                             26                                       369769 (56546-693516)                                0.5381 (vs. T4)
                                            T3                                             39                                      182419 (20984-1238682)                               0.8540 (vs. T4)
                                            T4                                            228                                      194408 (25828-973370)                                             
                                            T1+T2                                      42                                       235868 (33343-559008)                             0.9120 (vs. T3+T4)
                                            T3+T4                                     267                                     190657 (25819-1033833)                                            
N stage                                N0                                            68                                       207716 (19836-689249)                                             
                                            N1                                            48                                       138689 (38258-541982)                                0.7156 (vs. N0)
                                            N2                                            64                                      405239 (75359-1130294)                               0.1656 (vs. N0)
                                            N3                                           131                                     153547 (26931-1194487)                               0.4941 (vs. N0)
                                            N1+N2+N3                             243                                     190657 (38258-1033833)                               0.4428 (vs. N0)
M stage                               M0                                           276                                      173219 (27702-931007)                                        0.071
                                            M1                                            40                                      538487 (56401-1302995)                                            
TNM stage                          I                                                25                                       116680 (16622-564409)                                             
                                            II                                               58                                       274664 (19259-994673)                                  0.6092 (vs. I)
                                            III                                            216                                      180861 (38178-962672)                                  0.5177 (vs. I)
                                            IV                                              9                                       366437 (48032-1709539)                                 0.6963 (vs. I)
                                            II+III+IV                                283                                     203849 (26931-1033833)                                 0.5179 (vs. I)
Clinical outcome                Disease free                            116                                     311898 (43387-1149783)                                            
                                            Metastases                               15                                       151576 (7608-1195160)                            0.5729 (vs. DisFree)
                                            Death                                      183                                      147390 (25854-935614)                            0.1021 (vs. DisFree)
Number in each subgroup are the number of samples which have both gene quantity and clinical information.
GREM1 and tumour associated angiogenesis and
lymphangiogenesis markers. Gremlin1 promotes angiogenesis
through an interaction with kinase insert domain receptor
(KDR, also known as vascular endothelial growth factor
receptor 2, VEGFR2). In the present study, we evaluated the
correlation between GREM1 and key genes relevant to
angiogenesis and lymphangiogenesis in the TCGA cohort.
The expression of GREM1 in GCs was positively correlated
with most of the angiogenesis factors/markers, especially
fibroblast growth factor-2 (FGF2), fibroblast growth factor-
1 (FGF1), factor VIII (F8) and sphingosine 1-phosphate
receptor 2 (S1PR2) (Figure 5A-E). Furthermore, a positive
correlation was seen between GREM1 and most of the
lymphangiogenesis factors, especially vascular endothelial
growth factor C (VEGFC), podoplanin (PDPN), lymphatic
vessel endothelial hyaluronic acid receptor 1 (LYVE1) and
Fms related tyrosine kinase 4 (FLT4, also known as vascular
endothelial growth factor receptor 3, VEGFR3) (Figure 5F-
J). PCR showed a reduced expression of KDR and VEGFC
in HGC27GREM1sh cells after knockdown of Gremlin1
(Figure 5K).
Discussion
In this study, the expression of Gremlin1 in gastric cancer
specimens and normal gastric tissues was determined and
analysed. It was found that the expression of Gremlin1 in
gastric cancer was significantly elevated compared with
normal tissues. The increased expression of Gremlin1 in GC
was evident in the TCGA cohort. Further analyses showed that
Gremlin1 was positively correlated with tumour
growth/invasion and lymph node metastasis. Survival analyses
showed that increased expression of Gremlin1 in GCs resulted
in poorer OS and PFS. It can thus be suggested that the
elevated expression of Gremlin1 in GC is involved in disease
progression. Further evaluation using immunohistochemistry
will clarify its predictive potential for the prognosis of GC.
To clarify the mechanism of Gemlin1 involvement in GC
progression, we determined the influence of Gremlin1 on the
properties of GC cell lines. Knockdown of Gremlin1 in
HGC27 or its overexpression in AGS cell lines provided
contrasting models to examine the biological functions of
Gremlin1 in GC cells. Proliferation assay, colony formation
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Figure 1. Gremlin1 expression in GC and its clinical relevance. (A) Expression of GREM1 transcripts in GCs (n=274) and normal tissues (n=33)
in the TCGA GC cohort. (B) Correlation between GREM1expression and T staging, including T1 (n=13), T2 (n=70) T3 (n=107) T4 (n=75). (C)
GREM1 expression in primary tumours without positive lymph node (n=91) compared with those with lymphatic metastasis (n=171). (D) Expression
of GREM1 in tumours presented distant metastases (M1, n=18) in comparison with those had no distant metastasis (M0, n=243). (E) GREM1 and
overall TNM staging of the GCs including TNM-I (n=35), TNM-II (n=51), TNM-III (n=155) and TNM-IV (n=18). (F) Kaplan–Meier survival
analyses showed correlations between GREM1expression and overall survival of GC patients using the online platform (www.KMplot.com). The
cut-off value used in the analysis was 4560. (G) Correlation between GREM1expression and progression free survival (PFS) of GC was analysed
(www.KMplot.com), and the cut off value used in the analysis was 4307. *Represents p<0.05, ***represents p<0.001. HR: Hazard ratio.
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Figure 2. Gremlin1 regulates proliferation and tumourigenic capacity of GC cells. (A) Gremlin1 was examined for its mRNA expression in GC cell
lines using PCR. (B) Gremlin1 knockdown and overexpression in HGC27 and AGS were confirmed using PCR (left) and western blot (right),
respectively. Cell proliferation assay was performed for HGC27GREM1sh cells (C) and AGSGREM1exp cells (D) in comparison with the corresponding
controls. Colony formation assay was performed on HGC27GREM1sh cells (E) and AGSGREM1exp cells (F). Growth of the HGC27 GREM1sh (G) and
AGSGREM1exp (I) cells was examined using a 3D spheroid model. Size of 3-D acini of HGC27 GREM1sh cells (H) and AGSGREM1exp cells (J) was
determined using ImageJ compared with their controls. Minimal three independent experiments were performed for all experiments. Shown are
representative experimental data. *Represents p<0.05, **represents p<0.01; ***represents p<0.001.
and 3D spheroid growth assays revealed that Gremlin1
promoted proliferation, colony formation, and formation and
growth of spheroids of GC cells in vitro. The positive impact
on the proliferation and tumourigenic capacity of GC cells
is in line with its implication in disease progression. This is
also supported by a very recently published study in which
showed the tumourigenic potential of Gremlin1using an
organoid model (16). BMPs have been shown to inhibit
proliferation of epithelial cells and epithelium derived
cancerous cells through canonical signaling pathways, upon
binding to their receptors (17). Such an inhibitory effect on
proliferation was also evident for BMP2 in GC (5, 6). As a
BMP antagonist, the elevated expression of Gremlin1 in GC
plays a protective role by antagonizing the inhibition of
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Figure 3. Gremlin1 regulates the adhesion, invasion and migration of GC cells. Cell adhesion assay (A) and transwell invasion assay (B) was
performed to evaluate the impact of Gremlin1 on the adhesion and invasiveness of GC cell lines. Wounding assays were performed comparing
HGC27SC and HGC27GREM1sh with semi-quantification of migration area using Image J (D) and representative images are shown for each cell
lines (C). The wounding assay was employed to determine the migration of AGSpEF and AGSGREM1exp followed by semi-quantification of migration
area using Image J (E and F). Three independent experiments were performed. **Represent p<0.01, ***represent p<0.001.
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Figure 4. GREM1 and EMT in GC. (A) PCR were performed to test the expression of EMT markers in the GREM1knockdown HGC27 cells and
Gremlin1 overexpression AGS cells. Correlation between GREM1and EMT markers in the TCGA-GC cohort was analysed using Spearman tests,
results shown as a heatmap (B) and scatter plots of significantly related EMT markers (C-H).
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Figure 5. Association between GREM1 and angiogenesis/lymphangiogenesis in GC. Correlation between GREM1and angiogenesis markers were
analysed using Spearman tests, results shown as a heatmap (A) and scatter plots (B-E). Correlation between Gremmlin1 and lymphangiogenesis
markers were shown as a heatmap (F) and scatter plots (G-J). The expression of angiogenesis/lymphangiogenesis markers in the GREM1 knockdown
HGC27 cells and GREM1 overexpression AGS cells was examined using PCR (K).
BMPs on proliferation. However, the most involved BMP is
yet to be revealed. Furthermore, the expression profile of
different BMP receptors and intracellular downstream
molecules should also be considered in the context of tumour
microenvironment in order to explain the differential
responses to certain BMPs. This could be specific to certain
ligands and receptors in cancers (18). Further investigation
of other BMPs, BMP receptors, intracellular signaling
molecules and regulatory factors in GC will help to build up
a comprehensive understanding of the role of BMPs in GC. 
Unlike the effect on proliferation, functional assays showed
that Gremlin1 knockdown promoted invasion and migration
of GC cells by eliminating the antagonistic effect on BMP-
induced invasiveness and migration of cancer cells (19).
Interestingly, the invasion of AGSGREM1exp cells was also
increased in comparison with the AGSpEF cells, rather than
decreased. Crosstalk among different growth factors/cytokines
and their downstream signal transduction pathways may help
to answer this question. For example, BMP and its signalling
pathways are intricately linked to many other growth factors
and signaling pathways in cancer cells, including epidermal
growth factor receptor (EGFR) pathway (RTK/MAPK
pathway (20-22), PI3K/Akt pathway (23-25), HGF/MET
pathway (26, 27) [62, 63]and so on. The change in invasion
is the result of the integration of the intricate signal network.
Exploration of the interaction between these signaling
pathways may help to understand how Gremlin1 regulates the
invasion and migration of GC cells.
EMT is an important event during the development and
progression of cancer, causing disruption of epithelial
homeostasis that may lead to carcinogenesis. It is also a vital
part of the transformation of indolent tumour cells into a more
aggressive colony, leading to metastasis (28, 29). Regulation
of EMT by BMPs has been implicated in many studies
regarding organ development (30, 31) and cancer (32-35).
BMPs can induce EMT by both Smad-dependent (36-38) and
Smad-independent pathways (39, 40). For instance, BMP
signalling could directly activate the expression of the EMT
transcription factors, Snail, TWIST1 and MSX1/2 (36-38).
Regarding the Smad-independent pathway, BMP2 could
induce EMT and invasion through regulation of the PI3K/Akt
pathway (39, 40). In the current study, we found that the
expression levels of GREM1were negatively correlated with
the expression of ID1, ID2 and ID3, but were positively
correlated with Snai1, SNAI2 and TWIST1. It can be seen that
GREM1 may also be involved in EMT in gastric cancer, and
the specific mechanism needs further exploration.
Angiogenesis is indispensable for the development and
progression of both primary and secondary tumours. Our
study revealed that GREM1 was positively correlated with
angiogenic markers, suggesting that Gremlin1 is likely to
participate in the angiogenesis of GC by antagonizing BMP.
It has been shown that BMPs can affect directly and
indirectly angiogenesis. BMPs and their downstream Smads
can regulate proliferation, migration, or tubule formation of
vascular endothelial cells (41). On the other hand, BMPs
can regulate angiogenesis indirectly through regulation of
the expression of VEGF in both cancer cells and osteoblasts
(42). For example, BMP2 has been shown to promote
tumour-related angiogenesis through up-regulation of
VEGF via the p38 pathway in breast cancer (43). BMP9
has been shown to inhibit the proliferation of endothelial
cells, as well as to inhibit VEGF mediated angiogenesis,
via ACVRL1 and BMPR2 and downstream Smad1/5
signalling (44). In addition, Gremlin1 can directly target
VEGF receptors in vascular endothelial cells, promoting
angiogenesis as a direct agonist rather than through the
interaction with BMP ligands (45). At present, the specific
mechanism by which Gremlin1 promotes angiogenesis in
gastric cancer is yet to be clarified. However, the
expression profile of both BMP/BMP receptors and
VEGFs/VEGFRs should be considered.
Lymphangiogenesis plays an important role in cancer
metastasis, especially in the dissemination of cancer cells
through lymphatic vessels (46). In this study, the expression of
GREM1 in GCs with lymph node metastases was significantly
higher than that in GC without lymph node metastasis.
Furthermore, there was a positive correlation between GREM1
and lymphangiogenesis factors such as VEGFC, PDPN and
LYVE. The expression of VEGFC in HGC27GREM1sh cells was
indeed lower compared to the control cells. This suggested that
Gremlin1 may also be involved in GC by affecting
lymphangiogenesis which is yet to explored.
Conclusion
In summary, expression of Gremlin1 is increased in GC, and
elevated expression of Gremlin1 is significantly associated
with poorer survival of GC patients. Gremlin1 promotes
proliferation and tumourigenesis of GC cells in vitro.
Furthermore, Gremlin1 may be involved in EMT,
angiogenesis and lymphangiogenesis in GC. Further research
is required to identify the specific GCs in which Gremlin1
is indispensable for the disease progression, in order to
identify novel predictive and/or therapeutic targets.
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